NDA 021996 · Bausch and Lomb
Children'S Alaway
Ketotifen Fumarate · Ophthalmic
Last checked: Nov 19, 2026Latest source record: Apr 14, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Dec 1, 2006
Approved uses
1
Original approval plus efficacy supplements
Registered trials
34
20 Phase 3, 3 recruiting
FAERS reports
2,730
727 serious, 31 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 31, 2026.
Uses For the temporary relief of itchy eyes due to ragweed, pollen, grass, animal hair and dander.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- CHILDREN'S ALAWAY · KETOTIFEN FUMARATE EQ 0.025% BASE · SOLUTION/DROPS, OPHTHALMIC · Over-the-counter
- ALAWAY · KETOTIFEN FUMARATE EQ 0.025% BASE · SOLUTION/DROPS, OPHTHALMIC · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Ketotifen" as an intervention, any sponsor and status, largest first.
- Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic SolutionPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT05815758 · 512 participants · Start Apr 20, 2023 · Primary completion Sep 18, 2023
Drug: Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo); Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution · For: Allergic Conjunctivitis
Sites: Chandler, Arizona; Havre de Grace, Maryland; Andover, Massachusetts · 7 sites in all
- PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2Pivotal-lookingCompleted
University of CalgaryAcademic, hospital or other
NCT03582176 · 395 participants · Start Apr 26, 2019 · Primary completion Sep 29, 2024
Drug: Lactose Placebo; Ketotifen Fumarate 2mg and 1 more · For: Elbow Fracture; Elbow Injury; Elbow Dislocation
Sites: Baltimore, Maryland; Charlotte, North Carolina; Burlington, Vermont · 15 sites in all
- A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic DermatitisPivotal-lookingCompleted
Tanabe Pharma CorporationIndustry
NCT01840605 · 303 participants · Start Mar 2013 · Primary completion Nov 2013
Drug: Bepotastine besilate; ketotifen fumarate · For: Dermatitis; Atopic
Sites: Hokkaido, Japan
- Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic ConjunctivitisPivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00133627 · 229 participants · Start Apr 2005 · Primary completion Oct 2005
Drug: Ketotifen · For: Seasonal Allergic Conjunctivitis
Sites: Shanghai, China
- Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic ConjunctivitisPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT05591755 · 229 participants · Start Nov 18, 2022 · Primary completion Aug 9, 2023
Drug: Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution; Ketotifen fumarate ophthalmic solution 0.035% and 2 more · For: Seasonal Allergic Conjunctivitis
Sites: Louisville, Kentucky; Andover, Massachusetts; Goodlettsville, Tennessee · 6 sites in all
- A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.Pivotal-lookingCompleted
Faes Farma, S.A.Industry
NCT03479307 · 228 participants · Start Apr 7, 2018 · Primary completion Aug 9, 2018
Drug: Bilastine Ophthalmic Solution 0.6%; Ketotifen Ophthalmic Solution 0.025% (Zaditen) and 1 more · For: Allergic Conjunctivitis
Sites: Phoenix, Arizona; Torrance, California; Andover, Massachusetts · 6 sites in all
- Montelukast Post-Marketing Comparative Study With Ketotifen (0476-379)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00446056 · 188 participants · Start Sep 25, 2003 · Primary completion Jun 16, 2004
Drug: MK0476, montelukast sodium / Duration of Treatment: 4 Weeks; Comparator: ketotifen / Duration of Treatment: 4 Weeks · For: Asthma
- Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic ConjunctivitisPivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT05579730 · 188 participants · Start Oct 12, 2022 · Primary completion Jul 22, 2023
Drug: Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%; Brimonidine Tartrate 0.025% and 2 more · For: Allergic Conjunctivitis
Sites: Phoenix, Arizona; Andover, Massachusetts; Memphis, Tennessee · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- eye irritation489
- drug ineffective410
- eye pain204
- pruritus158
- treatment failure149
- ocular hyperaemia147
- urticaria126
- eye pruritus123
- headache120
- fatigue118
- nausea113
- condition aggravated112
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 5 |
| 2005 | 9 |
| 2006 | 10 |
| 2007 | 21 |
| 2008 | 73 |
| 2009 | 94 |
| 2010 | 11 |
| 2011 | 98 |
| 2012 | 124 |
| 2013 | 113 |
| 2014 | 23 |
| 2015 | 82 |
| 2016 | 156 |
| 2017 | 227 |
| 2018 | 150 |
| 2019 | 250 |
| 2020 | 226 |
| 2021 | 183 |
| 2022 | 149 |
| 2023 | 170 |
| 2024 | 163 |
| 2025 | 207 |
| 2026 | 186 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Evaluation of corneal staining with an antihistamine-releasing contact lens.
Pall B, Sun CK · Clin Exp Optom 2023 · Randomized Controlled Trial
- Bilastine 0.6% Preservative-free Eye Drops: A Once-daily Treatment for Allergic Conjunctivitis.
Gomes PJ, Ciolino JB, Arranz P, et al. · J Investig Allergol Clin Immunol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Management of Ocular Allergy Itch With an Antihistamine-Releasing Contact Lens.
Pall B, Gomes P, Yi F, et al. · Cornea 2019 · Multicenter Study, Randomized Controlled Trial
- Effect of ketotifen in obese patients with type 2 diabetes mellitus.
El-Haggar SM, Farrag WF, Kotkata FA · J Diabetes Complications 2015 · Randomized Controlled Trial
- Comparison of the central nervous system effects produced by six H1-receptor antagonists.
Simons FE, Fraser TG, Reggin JD, et al. · Clin Exp Allergy 1996 · Clinical Trial, Comparative Study
- Comparison of Pregabalin and Ketotifen in treatment of uremic pruritus in hemodialysis patients.
Shamspour N, Aflatoonian M, Khalili M, et al. · Dermatol Ther 2022 · Randomized Controlled Trial
Sponsor: Bausch and Lomb · Also marketed as Alaway
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.